Lytix Biopharma's NeoLIPA combination therapy meets primary endpoint in melanoma trial

Lytix Biopharma reported that its combination therapy NeoLIPA achieved its primary endpoint in a clinical trial evaluating its efficacy in treating melanoma.

Detected & updated continuously · Source: Nebula